Home page > OLD Wealth and Equity | Pharmaceuticals and Medical Devices | WTO Cancun Ministerial, September 2003 | Quality health systems and services | Medicines, health technology and health information | Irish Presidency priorities

Pharmaceuticals and Medicines

Please find all related articles below.

[EU-US trade agreement] Investor-state dispute settlement (ISDS) consultation: A missed opportunity?

On 27 March, the European Commission (EC) launched a public consultation on the investor-state dispute settlement (ISDS) chapter within the context of the Transatlantic (ie EU-US) Trade and Investment Partnership (TTIP). Weeks earlier, the EU Trade Commissioner put a halt to negotiations over the ISDS due to mounting criticism from civil society groups and the European Parliament (EP). 07 April 2014 - This consultation has been presented by the EC as a solution to increase transparency (...)

[Save the date] Patients’ Needs Driving Innovation in Global Health: March 10th, 2014

EPHA is organising a joint debate about the pivotal role that patients should play in creating innovative, affordable and quality technologies and products for poverty-related and neglected diseases. To register, please RSVP with your full name and contact details at anne.herrmann@dsw-brussels.org by March 6th.

[EU-US trade agreement] Briefing for EPHA members

EPHA is creating a briefing for its members to understand the potential impacts of the TTIP on public health. To add items to the briefing, please contact the EPHA Secretariat at leonardo@epha.org. The document is intended to raise awareness among EPHA members (plus their members) and EPHA partners. The Transatlantic Trade and Investment Partnership (TTIP) is a trade and investment agreement that is currently being negotiated between the European Union (EU) and the United States (US). (...)

EPHA news feed on the prospective EU-US Trade Agreement (TTIP) & its potential impact on public health - Subscribe!!

This week EPHA launched a weekly news feed about the latest developments around the prospective Transatlantic Trade and Investment Partnership (TTIP) – a free trade agreement currently being negotiated between the EU and the US and the potential negative effect it may have on public health outcomes on both sides of the Atlantic. To learn more about this topic, you can read: [EU-US trade agreement] Would it benefit Europe’s public health? This digest will primarily focus on (...)

[Corporate sovereignty] How trade policy gives companies tools to delay measures to protect public health

On 3 December 2013, Members of the European Parliament (MEP) Linda McAvan (S&D) and Carl Schlyter (Greens) hosted a debate in the European Parliament on the 514 cases that corporations have brought against governments. Some of the examples presented included the international tobacco giant Philip Morris suing the governments of Uruguay and Australia for introducing plain cigarette packaging. This debate is particularly relevant in light of current negotiations between the EU and the (...)

[European Council] Conclusions on Sustainable Health Systems - putting the spotlight on the health impacts of the crisis

On 10 December, Health Ministers unanimously adopted Council Conclusions on the Reflection Process on Modern, Responsive and Sustainable Health Systems, prepared by the Lithuanian Presidency of the Council of the EU. In the Conclusions the Member States acknowledge the core role of health for the economic prosperity and stress the importance of the principles of solidarity, universal health care accessibility as well as the horizontal principle “health in all policies”. (...)

[European Commission report] Personalised Medicine

The European Commission has recently published a Staff Working Document (SWD) exploring the potential of Personalised Medicine, reporting on recent developments in the EU legislation, as well as looking at the factors affecting the uptake of personalised medicine in healthcare systems. Personalised Medicine is now more close to be effective to patients, which means that treatments can be designed taking into account a specific patient group and hence able to tackle the problem with the (...)

[Press release] The clock is at five-to-twelve for antibiotic resistance

Brussels, 18 November – Today marks the 6th European Antibiotic Awareness Day (1), an initiative to raise awareness on antibiotic resistance (AMR), one of today’s most serious public health threats not only in Europe but worldwide. Over recent decades, growing mobility of the global population has increased the risk and incidence of cross-border diseases, and antimicrobials have been instrumental in preventing and treating such infections. AMR results from the overuse or (...)

[Save the date] Dangerous side effects: The public health impact of investor-state dispute settlement

In the context of several ongoing and upcoming trade negotiating rounds with amongst others the United States, India and Thailand, civil society will debate with Members of Parliaments and experts the impacts of the agreements on public health. This follows the conclusion of the first ever EU-wide investment protection chapter, in the trade agreement with Canada WHEN: Tuesday 3 December 2013 (13:30-15:30) WHERE: Room ASP 3H1- European Parliament, Brussels Hosted by MEP Linda McAvan (...)

[Joint press release] Leaked Commission research documents raise questions about whose interests are being prioritised

1 October, Brussels -Scientists, public health researchers and NGOs have reacted with grave concern in light of leaked copies of the European Commission’s proposed Health Research Programme 2014-2015 (part of Horizon2020) circulating in Brussels. They have raised questions regarding the preparation of this draft, given its failure to address the major personal, social, environmental and occupational risk factors of disease in favour of narrow research parameters focusing on (...)